Join to View Full Profile
1500 E Duarte RoadDuarte, CA 91010
Phone+1 626-218-2405
Fax+1 626-389-3058
Dr. Baird is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am an assistant professor in the Division of Lymphoma, Department of Hematology and HCT at City of Hope National Medical Center in Duarte, CA. I am boarded in Internal Medicine, Hematology, and Medical Oncology. I have a background in clinical and translational research, and specialize in CAR-T therapies for hematologic malignancies. My particular research interests lie in novel drug development and translational pathobiology for leukemia and lymphoma.
Clinical Expertise
- Hematologic oncology, Bone marrow transplantation, CAR-T Therapy
Education & Training
Stanford Health CareFellowship, Blood & Bone Marrow Transplant, 2020 - 2021- Stanford Health CarePost-Doctoral Fellowship, 2019 - 2020
- Stanford Health CareFellowship, Hematology and Medical Oncology, 2016 - 2019
University of Pennsylvania Health SystemResidency, Internal Medicine, 2014 - 2016- University of Pennsylvania Health SystemInternship, Internal Medicine, 2013 - 2014
University of Arkansas For Medical Sciences College of MedicineClass of 2013
Certifications & Licensure
CA State Medical License 2016 - 2026
PA State Medical License 2013 - 2016
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Richard V. Ebert Award Dept. of Internal Medicine, UAMS, 2013
- Graduated with Honors in Research UAMS College of Medicine, 2013
- Clinical Research Training Program (CRTP) Fellow OCRTME, National Institutes of Health (NIH), 2012
Clinical Trials
- Natural History of Sickle Cell Disease Start of enrollment: 2004 Apr 29
- Carbon Monoxide Levels and Sickle Cell Disease Severity Start of enrollment: 2012 Jan 26
- CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies Start of enrollment: 2017 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Autologous Transplant or CAR-T as Consolidation Options in MYC Rearranged Large B-Cell Lymphoma Patients in Remission After Salvage Treatments.Fateeha Furqan, Kwang W Ahn, Manmeet Kaur, Jinalben Patel, Stephen Ansell
American Journal of Hematology. 2025-07-01 - Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: Real-world analysis from CIBMTR.Kitsada Wudhikarn, Megan M Herr, Min Chen, Michael J Martens, John H Baird
Blood Advances. 2025-05-28 - 1 citationsNivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphoma.Matthew Mei, Joycelynne Palmer, Hun Ju Lee, Iris Isufi, Robert Chen
Hemasphere. 2025-05-01
Books/Book Chapters
Press Mentions
Scotland's Most Promising Scientists Awarded £12 MillionOctober 15th, 2020
Our Great Talent for Invention Will Lead Us Out of Darkness, Says LEO McKINSTRYApril 4th, 2020
Committees
- Ad Hoc Reviewer, British Journal of Haematology Editorial Board 2015 - Present
- Curriculum Author, Hospital of the Univ. of Pennsylvania Dept. of Medicine Nightfloat Curriculum Committee 2014 - 2016
Professional Memberships
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
